What Happens When You Have Ulcerative Colitis?
Title: What Happens When You Have Ulcerative Colitis?Category: Diseases and ConditionsCreated: 6/3/2022 12:00:00 AMLast Editorial Review: 6/3/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 3, 2022 Category: Nutrition Source Type: news
New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Elevating Ulcerative Colitis Treatment Expectations - Time to Expect Mo Elevating Ulcerative Colitis Treatment Expectations - Time to Expect Mo
Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2022 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Steroid Use May Increase Relapse Risk in Ulcerative Colitis Steroid Use May Increase Relapse Risk in Ulcerative Colitis
Steroid use may increase relapse risk in patients who have histologically active ulcerative colitis with a Mayo endoscopic subcore of 1.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Maintenance Mirikizumab Proves Mettle in Ulcerative Colitis
(MedPage Today) -- A maintenance program with mirikizumab offered clinical benefit in patients with moderate-to-severe ulcerative colitis who first responded to induction therapy with the drug, according to the phase III LUCENT-2 trial.
Among... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 26, 2022 Category: Gastroenterology Source Type: news
Etrasimod Shows Promise in Moderate to Severe Ulcerative Colitis
(MedPage Today) -- Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis (UC), according to an analysis... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 26, 2022 Category: Gastroenterology Source Type: news
Pfizer Ulcerative Colitis Drug Leads to Remission in a Third of Patients: Study Pfizer Ulcerative Colitis Drug Leads to Remission in a Third of Patients: Study
Nearly one third of patients with ulcerative colitis who received an experimental Pfizer drug in a clinical trial were in remission after a year of treatment, the drugmaker said on Tuesday.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 25, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids
INDIANAPOLIS, May 24, 2022 -- (Healthcare Sales & Marketing Network) -- In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, ... Biopharmaceuticals, Gastroenterology Eli Lilly, mirikizumab, ulcerative colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2022 Category: Pharmaceuticals Source Type: news
Crohn's Disease vs. Ulcerative Colitis (UC)
Title: Crohn ' s Disease vs. Ulcerative Colitis (UC)Category: Diseases and ConditionsCreated: 7/24/2017 12:00:00 AMLast Editorial Review: 5/23/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - May 23, 2022 Category: Nutrition Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Obesity Linked to Increased Risk for Crohn Disease
TUESDAY, May 17, 2022 -- Obesity, as measured by body mass index (BMI), is associated with an increased risk for Crohn disease (CD) but not ulcerative colitis (UC), according to a study published in the May issue of Clinical Gastroenterology&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 17, 2022 Category: Pharmaceuticals Source Type: news
How a Patient Encounter Affected a Clinician's Understanding of Ulcerative Colitis How a Patient Encounter Affected a Clinician's Understanding of Ulcerative Colitis
Oriana M. Damas, MD, reflects on a case in medical school of a young male patient with ulcerative colitis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
Treatment of Ulcerative Colitis: Shared Decision-Making Treatment of Ulcerative Colitis: Shared Decision-Making
Miguel Regueiro, MD, advises new clinicians to listen to their patients as part of the shared-decision-making process.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2022 Category: Consumer Health News Tags: Gastroenterology MDAngle Source Type: news
Treatment of Ulcerative Colitis: Maximizing the Benefit to Patients Treatment of Ulcerative Colitis: Maximizing the Benefit to Patients
Miguel Regueiro, MD, reflects on the gradual shift away from treatments for ulcerative colitis, such as the long-term prescribing of steroids and surgery.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2022 Category: Consumer Health News Tags: Gastroenterology MDAngle Source Type: news
